Author:
Yamagiwa Yoko,Tanaka Keitaro,Matsuo Keitaro,Wada Keiko,Lin Yingsong,Sugawara Yumi,Mizoue Tetsuya,Sawada Norie,Takimoto Hidemi,Ito Hidemi,Kitamura Tetsuhisa,Sakata Ritsu,Kimura Takashi,Tanaka Shiori,Inoue Manami,Abe Sarah Krull,Nomura Shuhei,
Abstract
AbstractIn Japan, hepatocellular carcinoma (HCC) is a leading cause of cancer mortality and hepatitis C virus infection is a major cause of HCC. We conducted a systematic review and meta-analysis of published studies evaluating patient response to antiviral therapy for chronic hepatitis C on the risk of HCC occurrence in Japan. Articles were searched using terms determined a priori through PubMed, screened by title and abstract, and selected by full-text assessment according to criteria determined a priori, including HCC occurrence in response to interferon (IFN)-based or IFN-free therapy, Japanese study, and 2 or more years of follow-up. We excluded studies on HCC recurrence. We calculated the pooled estimate of the crude incidence rate ratio with data from the selected studies using the person-years method with Poisson regression model and pooled estimate of the hazard ratio adjusted for potential confounders reported by the studies using a random effects model. A total of 26 studies were identified, all of which examined only IFN-based therapy as a result of the selection process. The pooled estimate (95% confidence interval [CI]) of 25 studies was 0.37 (0.33–0.43) for sustained virologic response (SVR) and 1.70 (1.61–1.80) for non-SVR for the HCC incidence rate per 100 person-years, and 0.22 (0.19–0.26) for the incidence rate ratio (SVR vs. non-SVR). The pooled estimate of the hazard ratio (95% CI) of HCC incidence adjusted for potential confounders of 8 studies was 0.25 (0.19–0.34). SVR to interferon therapy for chronic hepatitis C reduces the risk of HCC occurrence.
Funder
JSPS KAKENHI
National Cancer Center Research and Development Fund
Health and Labour Sciences Research Grants for Third Term Comprehensive Control Research for Cancer
Publisher
Springer Science and Business Media LLC
Reference69 articles.
1. International Agency for Research on Cancer. Biological Agents Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 100B. (2012).
2. United Nations. Sustainable Development Goal 3: Ensure Healthy Lives and Promote Well-Being for All at all Ages. Target3.3 By 2030, End the Epidemics of AIDS, Tuberculosis, Malaria and Neglected Tropical Diseases and Combat Hepatitis, Water-Borne Diseases and Other Communicable Diseases. (2015).
3. World Health Organization. Combating Hepatitis B and C to Reach Elimination by 2030. (2016).
4. World Health Organization. Fact Sheets: Hepatitis C. (2021).
5. de Martel, C., Georges, D., Bray, F., Ferlay, J. & Clifford, G. M. Global burden of cancer attributable to infections in 2018: A worldwide incidence analysis. Lancet Glob. Health 8, e180–e190. https://doi.org/10.1016/s2214-109x(19)30488-7 (2020).
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献